These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 24795335)
1. Early initial clinical experience with intravitreal aflibercept for wet age-related macular degeneration. Ferrone PJ; Anwar F; Naysan J; Chaudhary K; Fastenberg D; Graham K; Deramo V Br J Ophthalmol; 2014 Jun; 98 Suppl 1(Suppl 1):i17-21. PubMed ID: 24795335 [TBL] [Abstract][Full Text] [Related]
2. A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration. Park DH; Sun HJ; Lee SJ Int Ophthalmol; 2017 Oct; 37(5):1205-1214. PubMed ID: 27826933 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of outer retinal tubulations in eyes switched from intravitreal ranibizumab to aflibercept for treatment of exudative age-related macular degeneration. Massamba N; Dirani A; Butel N; Fardeau C; Bodaghi B; Ingram A; Lehoang P Graefes Arch Clin Exp Ophthalmol; 2017 Jan; 255(1):61-67. PubMed ID: 27397583 [TBL] [Abstract][Full Text] [Related]
4. Two-year functional and anatomical results after converting treatment resistant eyes with exudative age-related macular degeneration to aflibercept in accordance with a treat and extend protocol. Jørstad ØK; Faber RT; Moe MC Acta Ophthalmol; 2017 Aug; 95(5):460-463. PubMed ID: 28556485 [TBL] [Abstract][Full Text] [Related]
5. Aflibercept for Previously Treated Macular Edema Associated with Central Retinal Vein Occlusions: 1-Year Results of the NEWTON Study. Khurana RN; Chang LK; Bansal AS; Palmer JD; Wu C; Wieland MR Ophthalmol Retina; 2018 Feb; 2(2):128-133. PubMed ID: 31047339 [TBL] [Abstract][Full Text] [Related]
6. Comparison of anti-VEGF therapies on fibrovascular pigment epithelial detachments in age-related macular degeneration. Au A; Parikh VS; Singh RP; Ehlers JP; Yuan A; Rachitskaya AV; Sears JE; Srivastava SK; Kaiser PK; Schachat AP; Martin DF; Modi Y Br J Ophthalmol; 2017 Jul; 101(7):970-975. PubMed ID: 27913442 [TBL] [Abstract][Full Text] [Related]
7. Outcomes of Treatment-Resistant Neovascular Age-Related Macular Degeneration Switched from Aflibercept to Faricimab. Raimondi R; Falfeli T; Bogdanova-Bennet A; Varma D; Habib M; Kotagiri A; Steel DH; Grinton M Ophthalmol Retina; 2024 Jun; 8(6):537-544. PubMed ID: 38040055 [TBL] [Abstract][Full Text] [Related]
8. Comparison of Short-Term Choroidal Thickness and Retinal Morphological Changes after Intravitreal Anti-VEGF Therapy with Ranibizumab or Aflibercept in Treatment-Naive Eyes. Gharbiya M; Giustolisi R; Marchiori J; Bruscolini A; Mallone F; Fameli V; Nebbioso M; Abdolrahimzadeh S Curr Eye Res; 2018 Mar; 43(3):391-396. PubMed ID: 29166140 [TBL] [Abstract][Full Text] [Related]
10. Intravitreal ranibizumab versus aflibercept following treat and extend protocol for neovascular age-related macular degeneration. Abdin AD; Suffo S; Asi F; Langenbucher A; Seitz B Graefes Arch Clin Exp Ophthalmol; 2019 Aug; 257(8):1671-1677. PubMed ID: 31144055 [TBL] [Abstract][Full Text] [Related]
11. Ranibizumab versus aflibercept for the treatment of vascularized pigment epithelium detachment due to age-related macular degeneration. Rouvas A; Chatziralli I; Androu A; Mpougatsou P; Alonistiotis D; Douvali M; Kabanarou SA; Theodossiadis P Int Ophthalmol; 2019 Feb; 39(2):431-440. PubMed ID: 29404860 [TBL] [Abstract][Full Text] [Related]
12. Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD. Waizel M; Todorova MG; Masyk M; Wolf K; Rickmann A; Helaiwa K; Blanke BR; Szurman P BMC Ophthalmol; 2017 May; 17(1):79. PubMed ID: 28535756 [TBL] [Abstract][Full Text] [Related]
13. A single-arm, investigator-initiated study of the efficacy, safety and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration, previously treated with ranibizumab or bevacizumab: 6-month interim analysis. Singh RP; Srivastava S; Ehlers JP; Bedi R; Schachat AP; Kaiser PK Br J Ophthalmol; 2014 Jun; 98 Suppl 1(Suppl 1):i22-27. PubMed ID: 24836866 [TBL] [Abstract][Full Text] [Related]
14. Long-term outcomes of switching to aflibercept for treatment-resistant neovascular age-related macular degeneration. Spooner K; Hong T; Nair R; Chow NCC; Broadhead GK; Wijeyakumar W; Chang AA Acta Ophthalmol; 2019 Aug; 97(5):e706-e712. PubMed ID: 30740921 [TBL] [Abstract][Full Text] [Related]
15. Injection frequency and anatomic outcomes 1 year following conversion to aflibercept in patients with neovascular age-related macular degeneration. Messenger WB; Campbell JP; Faridi A; Shippey L; Bailey ST; Lauer AK; Flaxel CJ; Hwang TS Br J Ophthalmol; 2014 Sep; 98(9):1205-7. PubMed ID: 24795334 [TBL] [Abstract][Full Text] [Related]